RPL17 and glioblastoma: However, recent studies demonstrated that high TMB in glioblastoma is not broadly predictive of response to immune checkpoint blockade and that samples taken from tumors responsive to anti-PD1 therapy do not have a higher rate of somatic mutations [125,126].